Stockwinners Market Radar for June 01, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:52 EDT SentinelOne CEO: We are taking market share from incumbents - In an interview on CNBC's Mad Money, Tomer Weingarten said SentinelOne is taking share from a lot of incumbents who are antiquated with their technology stack. He is seeing less activity than expected out of Russia on the cyber front, but feels that could change at any time. He noted the company has "ample cash" on the balance sheet. Currently, it is focused on grabbing market share and investing for the long term, he added.

18:34 EDT Blue Safari Group Acquisition deposit $575K to extend business combination date - Blue Safari Group Acquisition has deposited into the company's trust account an aggregate of $575K, representing 10c per Class A ordinary share, in order to extend the period of time the company has to complete a business combination for an additional three month period, with the applicable deadline extended from June 14 to September 14. Bitdeer Technologies Holding and other parties have agreed to loan the company an aggregate principal amount of $1.99M in two tranches to fund any and all amounts required to extend the combination period for up to two times for an additional three month period each time. The loan bears no interest and is repayable only at the closing of a business combination by the company. On June 1, the company used $575K of the loan amount received to extend the Applicable Deadline to September 14.

17:34 EDT Phillips 66 VP Herman sells almost $4.9M in company shares - Phillips 66 VP Robert Herman disclosed in a filing that he had sold 47,200 shares of company stock at $102.82 per share on May 31, for a total transaction amount of 4,853,279.

17:03 EDT SailPoint announced expiration of HSR waiting period for Thoma Bravo merger - SailPoint announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to SailPoint's pending transaction with Thoma Bravo, a software investment firm. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the transaction contemplated by the Agreement and Plan of Merger of April 10. The consummation of the transaction remains subject to other customary closing conditions set forth in the Merger Agreement, including approval by SailPoint stockholders and receipt of certain other regulatory approvals. The transaction is still expected to close in the second half of 2022.

16:59 EDT Nextdoor announces $100M share repurchase agreement - Nextdoor "announced that its board has approved a share repurchase program with authorization to purchase up to $100M of its Class A common stock through June 30, 2024."

16:51 EDT UiPath up 7.8% at $18.14 after Q1 earnings beat, FY23 guidance raise

16:50 EDT NetApp rises 3.4% to $75.00 per share after Q4 earnings beat

16:38 EDT Chewy jumps 20% to $28.09 after Q1 profit beats estimates

16:35 EDT International Game subsidiary awarded contract extension from Kansas Lottery - International Game announced that its subsidiary, IGT Global Solutions Corporation, has signed a 10-year contract extension with the Kansas Lottery to deliver an enhanced version of IGT's Intelligen electronic gaming central system. The contract extension is expected to run through December 14, 2032.

16:33 EDT Riot Blockchain announces CFO transition - Riot Blockchain announced that, after a twenty year tenure with the company, Jeff McGonegal will retire from his position as CFO and move into a new role as Senior Advisor to Riot as of August 15th. Colin Yee, currently Head of Corporate & Financial Operations, has been selected by the board to succeed McGonegal as CFO as of August 15th , in accordance with Riot's succession planning process. McGonegal is expected to remain employed by the company through the term of his employment agreement ending February 7, 2023 to ensure a smooth transition. At the end of his employment term, McGonegal will continue supporting the company's strategic growth and operations. Yee joined Riot as Head of Corporate & Financial Operations in April 2022. He is currently responsible for the overall coordination and scalability of the company's corporate and financial functions, including risk management, information technology, human resources and financial planning. Prior to joining Riot, Yee was the CFO of a mid-market private equity firm specializing in renewable energy and infrastructure, the CFO of a publicly traded real estate company in Canada, and most recently, the COO and CFO of a family office with controlling interests in companies focused on construction and geothermal systems.

16:32 EDT Nyxoah says FDA approves Genio 2.1 for use in DREAM U.S. IDE pivotal study - Nyxoah SA announced that the FDA has approved the use of Nyxoah's next generation Genio 2.1 system for use in the company's DREAM U.S. IDE pivotal study. Genio 2.1's upgrades are entirely related to the external components of the Genio system, as the implantable stimulator remains unchanged.

16:31 EDT Ryerson acquires Ford Tool Steel, terms not disclosed - Ryerson announced its acquisition of Ford Tool Steels, a tool steel processor based out of St. Louis, Missouri. FTS has been in business for over 75 years, serving customers across the Midwest United States with tool steel and alloys, as well as cut-to-length sawing, plate sawing, and grinding and milling services. FTS's sawing and machining capabilities are aligned with those of Southern Tool Steel, a member of the Ryerson Family of Companies acquired in 2015. This strategic acquisition presents an opportunity to recognize synergies between the two brands as Ryerson expands its tool steel franchise.

16:30 EDT Blue Apron unlocks access to new customers with meal kits on Walmart.com - Blue Apron (APRN) "is launching a new offering on Walmart.com (WMT). Starting today, consumers can purchase a selection of meal kits without a subscription, from classic menu items to family favorite recipes. Blue Apron is the first and only meal-kit provider on the Walmart Marketplace platform, which serves millions of monthly active shoppers."

16:27 EDT Blue Apron launches selection of meal kits without subscription on Walmart.com - Blue Apron (APRN) is launching a new offering on Walmart.com (WMT). Starting now, consumers can purchase a selection of meal kits without a subscription, from classic menu items to family favorite recipes. Blue Apron is the first and only meal-kit provider on the Walmart Marketplace platform, which serves millions of monthly active shoppers. Blue Apron is offering four meal kits that serve up to 12, with plans to expand the options in the coming months.

16:24 EDT Boyd Gaming announces $500M increase to buyback authorization - Boyd Gaming announced that its Board of Directors has authorized a $500M increase to the Company's existing share repurchase program. The authorization will allow the Company to continue share repurchases as the Company concludes its previous repurchase authorizations, totaling $361M. CEO Keith Smith says: "This additional share repurchase authorization further reinforces our commitment to pursuing a balanced, robust capital return program. We intend to maintain repurchase activity of approximately $100M per quarter, augmented from time to time by opportunistic repurchases."

16:20 EDT Opiant begins rolling submission of NDA to FDA for opioid overdose treatment - Opiant Pharmaceuticals announced the filing of the first module of its New Drug Application for OPNT003, nasal nalmefene, for the treatment of opioid overdose. The module was submitted pursuant to a rolling submission, as agreed with the U.S. Food and Drug Administration during a pre-NDA meeting. As communicated previously, the Company expects to complete the submission of the NDA using the 505(b)(2) pathway in the second half of 2022. An estimated record 80,816 Americans died of an opioid overdose in 2021, a 17% increase over 2020 and a 62% increase from 2019, according to new data from the U.S. Centers for Disease Control and Prevention, CDC. Deaths involving synthetic opioids, including fentanyl, increased from 36,359 in 2019 and 56,516 in 2020, to an estimated 71,238 in 2021.1,2 "The opioid epidemic has evolved with the widening threat from potent synthetic opioids like fentanyl and there is significant evidence indicating that a new treatment option is needed," said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. "We believe the results from the pharmacokinetic and pharmacodynamic studies, in which OPNT003 demonstrated fast, strong, and long-lasting action and a well-tolerated safety profile, support OPNT003 as a potential new treatment option for opioid overdose. We look forward to working with the FDA to complete this rolling submission for OPNT003, nasal nalmefene, and we will provide an update when the NDA is completed."

16:17 EDT Terns Pharmaceuticals appoints Kerry Russell as chief medical officer - Terns Pharmaceuticals announced the appointment of Kerry Russell as chief medical officer. Russell will report to Erin Quirk, who remains president and head of research and development. Prior to joining Terns, Russell was vice president of late clinical development at Dicerna Pharmaceuticals, where she led the development of siRNA therapeutics for rare diseases from June 2020 until May.

16:16 EDT DHI Group: Dice taxonomy earns patent approval - DHI Group announced the United States Patent & Trademark Office has issued a patent for the taxonomy incorporated in its Dice service, which helps technologist candidates find more relevant jobs and customers find the right technology professionals to quickly fill immediate job openings. Dice's taxonomy associates job skill terms with a job skill listed on a candidate's profile by referencing a glossary of skills, then ranking the relationship between the terms and the actual skills by relevance. These actions are completed automatically by the technology covered in the patent.

16:12 EDT GameStop up 2% after Q1 sales beat expectations - Shares of GameStop are up $2.39, or 2%, to $121.95 in after-hours trading.

16:09 EDT HP Enterprise down 7% after reporting Q2 earnings, giving Q3 and FY22 guidance

16:08 EDT Oracle purchase of Cerner receives antitrust approval - Oracle (ORCL) announced that all required antitrust approvals have been obtained for its proposed acquisition of Cerner (CERN), including European Commission clearance. Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities. Oracle expects to complete the tender offer promptly following the expiration of that offer at midnight Eastern time on June 6, 2022. Completion of the tender offer remains subject to the conditions described in the tender offer statement on Schedule TO filed by Oracle with the U.S. SEC on January 19, 2022, as amended.

16:07 EDT Inter Parfums names Michel Atwood as new CFO - Inter Parfums announced that Russell Greenberg, Executive Vice President and Chief Financial Officer, will retire on September 6, 2022, and will be succeeded by Michel Atwood, a seasoned fragrance and finance executive, as Chief Financial Officer. Mr. Greenberg will stay with the company full time until September 30, 2022 to assist with the transition.

16:03 EDT NetApp reports Q4 billings up 16% at $2.02B - NetApp Q4 product revenue grew 6% year-over-year to $894 million, the fifth consecutive quarter of year-over-year growth. NetApp Public Cloud annualized revenue run rate (ARR)2 increased 68% year-over-year to $505 million.

15:44 EDT Zuckerberg says Javier Olivan to succeed Sandberg as Meta COO - Mark Zuckerberg, Founder and CEO at Meta, announced in a Facebook post: "It's the end of an era. After 14 years, my good friend and partner Sheryl Sandberg is stepping down as COO of Meta... I'm going to miss running this company with Sheryl. But I'm glad that she'll continue to serve on our board of directors so we can benefit from her wisdom and experience even after she transitions out of her day-to-day management role in the coming months. Looking forward, I don't plan to replace Sheryl's role in our existing structure. I'm not sure that would be possible since she's a superstar who defined the COO role in her own unique way. But even if it were possible, I think Meta has reached the point where it makes sense for our product and business groups to be more closely integrated, rather than having all the business and operations functions organized separately from our products... Marne Levine, our Chief Business Officer and the top business person who handles our partnerships, will report to Javier Olivan so that our Ads and Business Platform product group will be closer to the Meta Business Group. Javi will become our next Chief Operating Officer since he will now lead our integrated ads and business products in addition to continuing to lead our infrastructure, integrity, analytics, marketing, corporate development and growth teams. But this role will be different from what Sheryl has done. It will be a more traditional COO role where Javi will be focused internally and operationally, building on his strong track record of making our execution more efficient and rigorous." Reference Link

15:14 EDT Gannett restructuring into two distinct business units - Gannett Co. announced a strategic organizational restructuring with the creation of two new U.S. operating business units, Gannett Media and Digital Marketing Solutions, or DMS, which will be led by Maribel Perez Wadsworth and Kris Barton as Presidents of each business respectively. "The evolved corporate structure is designed to align Gannett's subject matter expertise and resources with favorable growth opportunities," the company stated.

14:10 EDT Phillips 66 'taps' FreeWire in support of its 1st U.S. EV charging program - Phillips 66 signed a letter of intent with FreeWire Technologies in support of its first electric-vehicle charging program in the United States, the two companies announced Wednesday. The announcement highlights Phillips 66's commitment to pursue lower-carbon solutions and comes as an endorsement of FreeWire's ultrafast, battery-integrated charging technology. The two companies will explore opportunities to deploy FreeWire's technology within Phillips 66's U.S. fueling stations and other strategic locations. "We are thrilled to play a leading role in Phillips 66's electrification plans that unlock new customer relationships with EV drivers," said Arcady Sosinov, FreeWire Founder and CEO. "As charging demand continues to surge, our battery-integr

14:04 EDT Huadi International Group Company Ltd trading halted, volatility trading pause

14:02 EDT North American rail traffic fell 2.5% for the week ending May 28 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending May 28, as well as volumes for May 2022. U.S. railroads originated 928,742 carloads in May , down 3.7% or 35,821 carloads, from May 2021. U.S. railroads also originated 1,102,558 containers and trailers in May, down 4.3% or 49,258 units, from the same month last year. Combined U.S. carload and intermodal originations in May 2022 were 2,031,300, down 4%, or 85,079 carloads and intermodal units from May 2021. "Rail traffic volumes in May reflected an economy that is a mixture of good and not-so-good," said AAR Senior Vice President John T. Gray. "Auto production and auto carloads seem to be slowly recovering; crushed stone and sand and food-related volumes are showing strength while intermodal had its best month since June 2021. On the other hand, carloads of chemicals fell for the first time in more than a year in May, while grain volumes continued to be disappointing when compared to those of 2021 and the latter half of 2020." North American rail volume for the week ending May 28, on 12 reporting U.S., Canadian and Mexican railroads totaled 330,951 carloads, down 2.5% compared with the same week last year, and 365,869 intermodal units, down 2.4% compared with last year. Total combined weekly rail traffic in North America was 696,820 carloads and intermodal units, down 2.5%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL), Wabtec (WAB), Berkshire Hathaway ( BRK.A, BRK.B) and GATX (GATX). Reference Link

13:15 EDT Adara Acquisition Corp (Class A Stock) trading resumes

13:01 EDT Southwest announces investment into SAFFiRE Renewables - Southwest Airlines announces an investment into SAFFiRE Renewables, a company formed by D3MAX as part of a Department of Energy-backed project to develop and produce scalable, sustainable aviation fuel, or SAF. "Funded with a DOE grant matched by Southwest's investment, SAFFiRE is expected to utilize technology developed by the DOE's National Renewable Energy Laboratory to convert corn stover, a widely available waste feedstock in the U.S., into renewable ethanol that then would be upgraded into SAF," the airline stated.

12:34 EDT Subaru of America reports May sales down 24.8% to 42,526 vehicles - Subaru of America reported 42,526 vehicle sales for May 2022, a 24.8% decrease compared with May 2021. The automaker also reported year-to-date sales of 220,620, a 20.8% decrease compared with the same period in 2021. "Subaru continues to face inventory challenges as the result of microchip and supply chain issues affecting automakers across the globe," the company said.

12:21 EDT Bragg Gaming completes $30M acquisition of Spin Games LLC - Bragg Gaming Group has completed its previously announced acquisition of Spin Games LLC in a cash and stock transaction valued at approximately $30M. The Spin Games acquisition provides for a differentiated and widely distributed iGaming product offering and accelerates Bragg's North American growth, Bragg said in a statement. Bragg will immediately leverage Spin's U.S. iGaming relationships to introduce new proprietary and exclusive third-party online casino content developed to address the preferences of U.S. and Canadian players and to cross-sell its existing player-popular European casino content, it added.

12:03 EDT Honda reports May U.S. sales down 57.3% to 75,491 vehicles - American Honda reported May sales of 75,491 vehicles, down 57.3% year-over-year, with "supply constrained and inventories at historic lows." Continued strong retail demand yields record high turn rates of over 80% for Honda brand and more than half of Civic and CR-V sales are pre-sold before they reach Honda dealer lots, the company stated. Reference Link

12:02 EDT Napco Security awarded school security project for Pepperdine University - NAPCO Security Technologies announced that its products have once again been selected for use in a school security project at Pepperdine University in Malibu, CA. Pepperdine has approximately 9,500 students enrolled at its Malibu, CA. campus The project includes the installation of NAPCO's Alarm Lock division ArchiTech locks in the university's classrooms. Richard Soloway, CEO of NAPCO commented, "We are pleased to report this school security project at Pepperdine University, which has used NAPCO products in multiple projects over the years. The security of our schools remains a very important issue, as we continue to witness horrific events around the country. NAPCO continues to be a leader in school security products and solutions, and we would like to thank Pepperdine for continuing to choose our products and being a highly valued customer."

12:00 EDT Signify Health falls -11.7% - Signify Health is down -11.7%, or -$1.59 to $12.04.

12:00 EDT Salesforce rises 10.3% - Salesforce is up 10.3%, or $16.55 to $176.79.

12:00 EDT Avaya rises 13.3% - Avaya is up 13.3%, or 49c to $4.18.

11:55 EDT Suburban Propane reports agreement with Adirondack Farms - Suburban Propane Partners announced an agreement to construct, own and operate a new biodigester system with Adirondack Farms in Clinton County, New York for the production of renewable natural gas. This project further expands the portfolio of clean energy investments under the company's wholly-owned subsidiary, Suburban Renewable Energy, LLC, which was formed in January 2022 to support the Partnership's strategic goal of building a renewable energy platform, the company said in a statement.

11:31 EDT Huron names J. Ronald Dail COO, succeeding C. Mark Hussey - Huron announced that J. Ronald Dail will succeed C. Mark Hussey as COO effective July 1, 2022. Upon his promotion, Dail will report to Hussey, Huron's president. Hussey will remain president until he becomes CEO and president on January 1, 2023, as part of the Company's previously announced CEO transition. "With the significant growth opportunity ahead for all three of our operating segments, we have a meaningful opportunity to efficiently expand our growing business on a global scale. I am confident that under Ronnie's leadership we will further optimize our business while focusing on accelerated revenue growth," said James H. Roth, CEO. Dail will assume responsibility for the company's operations, human resources and marketing organizations. He will be responsible for ensuring operational excellence across the company while supporting Huron's strategy of achieving consistent revenue growth and improved profitability.

11:09 EDT AmerisourceBergen says will introduce FY23 guidance in November - AmerisourceBergen management continue presenting at the company's investor day meeting.

10:47 EDT AmerisourceBergen sinks 4% to $148.18 as investor day continues

10:44 EDT JPMorgan CEO warns 'brace yourself' for coming 'hurricane' - Asked at the Sanford C Bernstein Strategic Decisions conference about the "degree of difficulty" he attaches to the task in front of the Fed right now, JPMorgan CEO Jamie Dimon replied in part: "I said I said there are 3 things that we're going through, which are -- I hate the word unprecedented, but are kind of unprecedented. And you got to put this in back of your mind when you haven't -- when you've seen things that have never happened before, then you have to question your ability to predict, okay? One is huge growth in this country, driven by fiscal and monetary stimulation. That isn't a normal recovery, okay? And that fiscal stimulation is still in the pocket books of consumers. They're spending it. They're spending at very strong levels. And the data is completely distorted. Distorted by inflation, distorted by -- they went from goods back to services. It's distorted by all the things... The Fed has to meet this now with raising rates... And the new part of this isn't the raising rates, it's the QT. The QT has -- we've never had QE before like this. Therefore, we've never had QT like this. So you're looking at something that's going to be writing history books on for 50 years. What was QE, what worked, what didn't work. I think a lot of parts of QE backfired. I think the negative rates was probably a huge mistake for a whole bunch of different reasons I can bore you with now, but they have to raise rates. It might be they have to do QT. They do not have a choice because there's so much liquidity in the system. They have to move some of the liquidity to stop the speculation to reduce home prices and stuff like that. And you've never been through QT... That's a huge change in the flow of funds around the world. I don't know what the effect of that is... And the third thing is Ukraine that you've not had a European land war since 1945, okay? And you -- and the complexity of Ukraine is we don't know the outcome... Wars go bad, they go south, they have unintended consequence. And this happens to be rolling the commodity markets of the world, wheat, oil, gas and stuff like that, which, in my view, will continue. We're not taking the proper actions to protect Europe from what's going to happen in oil in the short run... And we're not dealing with these challenges. So those 3 things fiscally induced growth, QT, Ukraine war... Look, I'm an optimist. I said they're storm clouds, they're big storm clouds here. It's a hurricane. Right now, it's kind of sunny, things are doing fine. Everyone thinks the Fed can handle this. That hurricane is right out there down the road coming our way. We just don't know if it's a minor one or Superstorm Sandy or Andrew or something like that. And you got to brace yourself. So JPMorgan is bracing ourselves, and we're going to be very conservative in our balance sheet on -- with all this capital uncertainty, we're going to have to take actions, and I kind of want to shed nonoperating deposits again, which we can do in size to protect ourselves, so we could serve clients in bad times. And so that's the environment we're dealing with. And I think it's okay to hope that will end up okay. I hope it. That's my goldilocks, I hope. The hell knows." In late morning trading, JPMorgan shares are down about 2%, or $2.41, to $129.82 while other mega-cap banks including Bank of America (BAC), Citi (C) and Wells Fargo (WFC) are also trading lower.

10:40 EDT AbbVie: Phase 3 SELECT-AXIS 2 program met primary endpoint - AbbVie announced the presentation of full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib, an oral therapy, in adult patients with active non-radiographic axial spondyloarthritis and patients with treatment-refractory active ankylosing spondylitis with an inadequate response to biologic disease-modifying antirheumatic drugs. Both studies met the primary endpoint of Assessment of SpondyloArthritis international Society 40 percent response criteria at week 14 versus placebo. In the SELECT-AXIS 2 nr-axSpA study, significantly more nr-axSpA patients achieved the primary endpoint of ASAS40 at week 14 with upadacitinib versus placebo. Statistical significance was also achieved in the first 12 of 14 multiplicity-controlled secondary endpoints compared to placebo at week 14 including change from baseline in patient's assessment of total back pain, Bath Ankylosing Spondylitis Functional Index, Ankylosing Spondylitis Disease Activity Score Low Disease Activity, Ankylosing Spondylitis Quality of Life, and MRI Spondyloarthritis Research Consortium of Canada score for SI joints. These findings, for which AbbVie disclosed topline results in 2021, were submitted as part of the regulatory applications to the U.S. Food and Drug Administration and the European Medicines Agency to treat adults with active nr-axSpA with objective signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs.

10:02 EDT BAE Systems to provide 500+ electric drive systems for Ontario bus fleets - BAE Systems has been selected by the Toronto Transit Commission to provide more than 335 electric drive systems for its new fleet of zero-emission capable hybrid transit buses. This follows an order of 165 additional Series-ER systems for nearby Mississauga Transit, supplying Ontario transit agencies with next-generation technology to reduce fuel use and enable infrastructure-free zero emissions operations across its fleets. BAE Systems' Series-ER system offers significant zero emission capabilities to assist a transit agency's transition to a full zero-emission operation. Series-ER features the company's next-generation components that use advanced materials and a lightweight, compact design to increase electrical efficiency. The Ontario fleet orders extend the footprint of the company's technology to more than 15,000 transit buses worldwide.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -7.6% - ProShares UltraShort Bloomberg Natural Gas is down -7.6%, or -$1.83 to $22.21.

10:00 EDT Livent falls -9.0% - Livent is down -9.0%, or -$2.85 to $28.93.

10:00 EDT Butterfly Network rises 13.8% - Butterfly Network is up 13.8%, or 42c to $3.47.

09:58 EDT Bark falls 10% after Q4 results miss expectations - Shares of Bark are moving lower after the company reported Q4 results last night. Bark's adjusted earnings per share of (15c) and revenue of $128.8M missed the consensus expectations of (2c) and $138.5M, respectively. Bark sees fiscal 2023 revenue of $556M, below the consensus of $614M, and Q1 revenue of $130M, below the $135M expectations. The company added 1.2M new subscriptions in fiscal 2022, bringing its year-end total to 2.3M. Average order value of $30.06 was up $1.32, or 4.6%, compared to fiscal 2021. Shares of Bark are down 10% to $2.25 in early trading.

09:47 EDT S&P Global falls -9.3% - S&P Global is down -9.3%, or -$32.63 to $316.85.

09:47 EDT Victoria's Secret rises 8.9% - Victoria's Secret is up 8.9%, or $3.67 to $44.88.

09:47 EDT Salesforce rises 11.6% - Salesforce is up 11.6%, or $18.64 to $178.88.

09:37 EDT Icosavax trading resumes

09:32 EDT Icosavax trading halted, volatility trading pause

09:28 EDT Maris-Tech initiates up to $1M share repurchase plan process - Maris-Tech announced that its board of directors has authorized a share repurchase plan allowing the Company to invest up to $1M to repurchase its ordinary shares, no par value.

09:23 EDT Bark lower after Q4 results miss expecations - Shares of Bark are moving lower after the company reported Q4 results last night. The company's adjusted earnings per share of (15c) and revenue of $128.8M missed the consensus expectations of (2c) and $138.5M, respectively. Bark sees fiscal 2023 revenue of $556M, below the consensus of $614M, and Q1 revenue of $130M, below the $135M expectations. The company added 1.2M new subscriptions in fiscal 2022, bringing its year-end total to 2.3M. Average order value of $30.06 was up $1.32, or 4.6%, compared to fiscal 2021. Shares of Bark are down 8% to $2.29 in premarket trading.

09:18 EDT Marqeta working with global retail bank Klarna on Klarna Card - Marqeta announced it is working with Klarna, a global retail bank, payments and shopping service, to power its new Klarna Card. The Klarna Card will bring the company's popular "Pay in 4" service to a physical Visa card, empowering consumers to pay over time in four equal, interest-free payments for any in-store or online purchase. The Klarna Card is now available to US consumers, and comes amid Klarna's rapid growth in the US, which continues to be Klarna's fastest-growing key market by volume. Klarna began using Marqeta's modern card issuing platform in the United States in 2018, to power virtual cards across multiple product offerings. "Our US customer base is growing rapidly and we've seen tremendous demand for our new Klarna Card offering. By working with Marqeta, we were able to quickly launch a brand new card program with seamless flexibility and controls," said David Sykes, Chief Commercial Officer at Klarna. "By expanding our partnership with Marqeta, we're leveraging their payments expertise to provide our customers with an unmatched user experience that will ultimately help our business grow."

09:14 EDT Magellan, Enterprise, ICE update terminal transfers of Midland WTI AGC futures - Magellan Midstream Partners (MMP), Enterprise Products Partners (EPD) and Intercontinental Exchange, (ICE) announced that the "no-charge" arrangement between the Magellan East Houston and the Enterprise Crude Houston terminals to transfer crude oil delivered through the Midland WTI AGC futures contract has been expanded to include deliveries conducted via ICE's Exchange for Physical and Alternative Delivery Procedure mechanisms. If customers take an HOU futures position to delivery and they are not matched by the exchange at the buyer's preferred terminal, the barrels are transferred between the MEH and ECHO terminals at no cost. Magellan and Enterprise are expanding this arrangement to now include HOU futures customers who take delivery via ICE's EFP or ADP mechanisms at one terminal and desire to transfer the barrels to the other terminal. "Expanding the free pump-over to include EFP and ADPs provides customers added flexibility to optimize their use of capital while still realizing the savings on the transfer costs they would otherwise incur," said Jeff Barbuto, Global Head of Oil Markets at ICE. The waived transfer costs apply to EFP and ADP deliveries in addition to all volume that goes to delivery through the HOU futures contract and is executed in accordance with ICE's rules, and will remain in effect through March 31, 2023. A 10-cent per barrel charge will continue to apply for all other general transfers meeting HOU quality specifications. The EFP mechanism allows participants to exchange HOU futures positions for the equivalent quantity of underlying physical Midland WTI barrels in the same delivery month. The ADP mechanism allows a buyer and seller to vary the terms of the delivery including, but not limited to, the location. For questions or information regarding EFPs and ADPs, please refer to ICE's rules. Since the contract began trading earlier this year, approximately 67,800 HOU futures have traded, representing 67.8 million barrels, including a record volume day on March 10 of 3,065 contracts. Open interest is at 2,647 contracts and goes out to January 2023.

09:12 EDT Euronet's epay division expands Renewal recurring billing solution - epay announced additional launches for Renewal, its recurring billing solution. This expansion includes the following channel partners and countries: Harvey Norman in Australia, Altibox Nordics, Cyberport and MediaMarktSaturn Retail Group in Germany, Etisalat UAE, the telecoms pillar of e& and Sharaf DG in the UAE, Singtel in Singapore and additional retailers in Mexico. More countries and retailers are already being planned and will be announced when available.

09:09 EDT Envestnet acquires 401kplans.com retirement plan marketplace - Envestnet announced its acquisition of 401kplans.com, a digital 401(k) retirement plan marketplace that streamlines retirement plan distribution and due diligence among financial advisors and third-party administrators. The 401kplans.com digital marketplace, available online and via mobile app, walks advisors through a documented due diligence process when considering plan providers. The platform delivers pricing from most 401(k) providers-thanks to direct integrations with more than 36 plan recordkeepers. 401kplans.com has grown to nearly 28,000 advisors with accounts on the platform and working relationships with broker-dealers.

09:07 EDT Verus International signs JV with Flord - Verus International announced that it has entered into a joint venture with Flord, a maker of premium rare cannabinoids. Under the terms of the JV, Verus will gain exclusive distribution rights and will be a 50% partner in the sale of Flord products in the United States. The current plan is to roll out various Flord cannabinoid-based SKUs over the next several months, with a goal to reach $3M in sales by year end.

09:06 EDT F.N.B. to acquire UB Bancorp for approximately $117M - F.N.B. and UB Bancorp signed a definitive merger agreement for FNB to acquire UB Bancorp, including its wholly-owned banking subsidiary, Union Bank, in an all-stock transaction valued at $19.56 per share, or a fully diluted market value of approximately $117M. Union Bank, based in Greenville, North Carolina, has approximately $1.2B in total assets, $1.0B in total deposits of which approximately 40% are non-interest bearing, and $0.7B in total loans and leases as of March 31, 2022. Union Bank operates 15 full-service banking offices in 12 counties located throughout Eastern and Central North Carolina. Following the merger, FNB will have approximately $43B in total assets, $35B in deposits and $28B in total loans. Stockholders of UB Bancorp will be entitled to receive 1.61 shares of FNB common stock for each share of UB Bancorp common stock they own. FNB expects the merger to be approximately 2% accretive to EPS with fully phased-in cost savings on a GAAP basis in addition to enhancing FNB's profitability metrics. FNB anticipates the tangible book value per common share impact to be de minimis at less than 1% and expects the CET1 ratio to remain unchanged on a proforma basis at closing. FNB and UB Bancorp expect to complete the transaction in late 2022 after satisfaction of customary closing conditions. Union Bank will merge with and into FNB's subsidiary, First National Bank of Pennsylvania.

09:05 EDT Transcode Therapeutics receives NIH notice of award totaling $2.3M - TransCode Therapeutics announced that it was awarded the second tranche of funding from a Fast-Track Small Business Innovation Research grant from the National Cancer Institute of the NIH. The SBIR award, totaling $2.3 M, supports the continued clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate for the treatment of advanced solid tumors. The company achieved the first milestone related to the SBIR grant during the first quarter of 2022 -triggering a payment of $1.1M as the second tranche of the award.

09:05 EDT Embark Technology partners with Texas Law Enforcement Agency - Embark Trucks shared an update on its progress to develop an emergency vehicle interaction capability for Embark-powered autonomous trucks to identify, stop for, and interface with law enforcement vehicles. Embark is working closely with the Texas Department of Public Safety, Texas DPS, to train Embark-powered trucks to identify law enforcement vehicles in situations such as traffic stops, and to develop communication protocols and standard operating procedures between autonomous trucks and law enforcement officers. Embark plans to publicly demonstrate the emergency vehicle interaction capability later this summer. "Our technical roadmap represents a measurable path to commercialization of autonomous trucks, and making sure law enforcement can safely and intuitively interact with autonomous trucks is a 'must' for deployment," said Emily Warren, Head of Public Policy at Embark. "Our work with Texas DPS prioritizes safety as we achieve this key technical milestone, and enables us to create a scalable emergency vehicle interaction model that can work across Texas and the U.S. Sunbelt."

09:03 EDT Spark Networks announces exploration of strategic alternatives - Spark Networks announced that it has initiated an exploration of strategic alternatives. As part of this process, the company plans to consider a wide range of options including a potential sale, merger or other strategic transaction, and continuing to operate as a public, independent company. "Spark is thriving from an operational standpoint and is well-positioned to return to sustainable revenue growth," said Eric Eichmann, the company's CEO. "Following approaches by a number of parties interested in a potential transaction, we believe now is an opportune time to explore a range of potential strategic alternatives." The company has engaged Moelis & Company LLC to act as its financial advisor and Jones Day to act as its legal advisor in connection with the review.

09:03 EDT Heartland Express acquires Smith Transport, related companies, for $170M - Heartland Express announced that it has acquired 100% of the equity of dry van truckload carrier Smith Transport, Inc. and related entities, for an aggregate value of approximately $170M.

09:01 EDT LiqTech announces new order for marine scrubber market - LiqTech announced a new order for the marine scrubber market, leveraging the company's proprietary water filtration system technology. The order, which covers two separate marine vessels, is expected to be delivered before the end of 2022.

08:58 EDT Myers Industries announces accretive acquisition of Mohawk Rubber Sales - Myers Industries announced that it has acquired the assets of Mohawk Rubber Sales of New England which was financed with its revolving credit facility. Mohawk Rubber Sales is a auto aftermarket distributor. "We are extremely pleased to announce the addition of Mohawk Rubber Sales to the Myers' family. Mohawk an its team bring complementary geographic coverage, additional sales and customer service capability, and meaningful scale to our Distribution Segment," said Mike McGaugh, President and CEO of Myers Industries. "Mohawk's business model is similar to our own, and this transaction is another example of our team's ability to find accretive opportunities to expand and grow our businesses - accelerating our progress against Horizon 1 of our 3-horizon strategy." Brian McGeoghegan, Owner of Mohawk Rubber Sales, said, "My team and I are thrilled to be joining the Myers family and believe Myers' culture and values align directly with our own. We've long admired Myers Tire Supply and its leading position in the tire repair and retread market and believe that Mike and his senior leadership team have repositioned the business for long-term success. We bring complementary assets and services, which will help both of our businesses achieve scale and efficiencies. Our collective focus on strong service and innovative products will create the best solutions in the market today and deliver enhanced value for our customers." Founded in 1932, Mohawk Rubber Sales has grown into one of the country's leading providers of tire repair distribution across traditional and online channels. The Company is headquartered in Hingham, MA and has four strategically located distribution centers across the United States located in Hingham, MA, Alpharetta, GA, Salt Lake City, UT, and Houston, TX. In 2021, Mohawk's revenues were approximately $65M. Mohawk will be integrated into the Myers' Distribution segment. The transaction provides both growth and cost synergy opportunities and is expected to be accretive to earnings in 2023.

08:53 EDT Sky Technologies places initial production orders for smart home products - Sky Technologies (SKYX) announced that the company has placed initial production orders for hundreds of thousands of Sky safe smart home products, positioning the company for its initial commercialization planned for the second half of 2022. Sky Technologies is in the process of initiating orders through General Electric (GE) approved factories for the production of its safe smart connected SkyPlug products. The company remains on-track for pre-sales to begin in the second half of 2022.

08:45 EDT RedBall Acquisition, SeatGeek agree to terminate combination agreement - RedBall Acquisition Corp, a publicly traded special purpose acquisition company, and SeatGeek, announced that on May 31, 2022 the companies have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization with immediate effect. The parties decided to terminate the Business Combination Agreement as a result of current unfavorable market conditions, particularly impacting growth technology companies. As required by Cayman Islands law, RedBall will convene the extraordinary general meeting of RedBall's shareholders scheduled to be held on June 1, 2022 to approve the proposed business combination. However, as a result of the termination of the Business Combination Agreement, at the extraordinary general meeting, RedBall intends that none of the proposed resolutions to approve the Business Combination Agreement and the connected matters concerning the transactions contemplated thereby would be put forward for the consideration and approval of RedBall's shareholders and that the extraordinary general meeting would be adjourned indefinitely.

08:44 EDT Raymond James completes acquisition of TriState Capital - Raymond James Financial (RJF) announced that it has completed the previously announced acquisition of TriState Capital Holdings (TSC). "The strategic and cultural fit between Raymond James and TriState has been continually reinforced as our teams have worked toward this point over the last few months," said Raymond James Chair and CEO Paul Reilly. "Our collective focus on client-first values and a long-term horizon are unique and a true differentiator for our firms. I'm thrilled to officially welcome TriState Capital to the Raymond James family and look forward to continue growing together." As a result of the acquisition, each share of TriState Capital common stock was converted into the right to receive $6.00 in cash and 0.25 shares of Raymond James common stock, which represents per share consideration of $30.62 based on the closing price of Raymond James common stock on May 31, 2022. Shares of TriState Capital ceased trading after the closing of the NASDAQ stock market on May 31, 2022.

08:43 EDT RedBall Acquisition, SeatGreek mutually agree to terminate business combination

08:43 EDT Guardion Health Sciences announces agreement with OmegaQuant Laboratories - Guardion Health Sciences announced an agreement with OmegaQuant Laboratories to provide Guardion with analytic testing and laboratory support services for current and future products. Guardion is a clinical nutrition company that offers a portfolio of science-based, clinically-developed products that are designed to support the health needs of consumers, healthcare professionals and providers and their patients. OmegaQuant is an independent, CLIA-certified laboratory that offers an extensive suite of clinical tests to researchers, clinicians and the public, including Omega-3 Index, Vitamin D, Prenatal DHA and Mother's Milk DHA testing. "This relationship with OmegaQuant positions us to conduct a variety of research projects around both our current product lines, as well as to evaluate future products for efficacy," commented Bret Scholtes, Guardion's Chief Executive Officer. "While we are still in the early stages of the relationship, we anticipate applying the Omega-3 Index test to advance the science of our current products, including the recently launched Omega Boost 1,200 mg Omega-3 Gel Bites recently launched under the Guardion flagship Viactiv brand."

08:41 EDT KemPharm: Research affirms SDX's lower potential for abuse - KemPharm announced that a manuscript summarizing the results of three clinical studies involving serdexmethylphenidate, KemPharm's prodrug of dexmethylphenidate, was published in the peer-reviewed journal, Current Medical Research & Opinion. The research concluded that SDX has significantly lower potential for abuse and minimal stimulant-like adverse events compared to d-MPH. SDX is the sole active pharmaceutical ingredient in KP1077, KemPharm's lead clinical product candidate. KemPharm is developing KP1077 as a treatment for idiopathic hypersomnia, a rare neurological sleep disorder, and narcolepsy. SDX is also primary active pharmaceutical ingredient in AZSTARYS, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients ages six and older being commercialized in the U.S. by Corium, Inc. The U.S. Drug Enforcement Agency has classified SDX as a Schedule IV controlled substance based on evidence suggesting SDX has a lower potential for abuse when compared to d-MPH, a Schedule II controlled substance.

08:39 EDT Forbes Global Media ends SPAC deal with Magnum Opus Acquisition - Forbes Global Media Holdings announced that its shareholders have terminated the Business Combination Agreement with Magnum Opus Acquisition , a special purpose acquisition company. Forbes announced record revenue and earnings last year, and has already exceeded the business forecast for 2022 it outlined in its initial investor deck. "The Forbes brand is a sought-after and trusted brand with more than 100 years of equity that is synonymous with success and validation," said Mike Federle, CEO, Forbes. "Our digital transformation has delivered double-digit revenue and EBITDA growth over the past year, which not only significantly outperformed the financial targets provided at the start of the SPAC transaction last year but continues to deliver high quality cashflows and compelling year-over-year and sequential growth since then. This is a testament to the incredible team we have assembled at Forbes that is delivering across our Media, and Brand Extensions business, as well as our newer consumer conversion strategy that has shown triple digit revenue growth over the past two years."

08:38 EDT QuickLogic awarded new $3.0M eFPGA contract - QuickLogic was awarded a new eFPGA contract for a previously announced foundry / process node combination, worth approximately $3.0M. This award brings the aggregate value of all eFPGA engagements since July 2021 to more than $9.0M. The company will leverage its Australis eFPGA IP Generator, launched in September 2021, to implement the customer's specific eFPGA configuration. This tool quickly generates custom eFPGA IP, optimized for power, performance, and area, for nearly any foundry/process node combination. Initial revenue from this contract is expected to be recognized beginning this quarter and continue through June of 2025, with follow-on revenue expected after the contract period.

08:37 EDT StoneCo to submit reduction in voting power concentration to BCB - StoneCo announced that it will submit to the Brazilian Central Bank a technical requirement of change of control. Following a series of Governance enhancements, the departure of our Co-Founder Eduardo Pontes from the company's Board of Directors and his desire to convert his interests in Class B super-voting shares into Class A shares directly owned by his family vehicles, Stone Pagamentos S.A. and Stone Sociedade de Credito Direto S.A., subsidiaries of the company, will submit to the Brazilian Central Bank a technical requirement of change of control. As a result of the detachment of Eduardo Pontes from the Founders' Holding Company and consequently the conversion of his original Super Voting Class B to Regular Voting Class A shares, the two co-Founders of the company would collectively and individually have less than 50% of the voting power. "The Company has been making continued efforts over the past months to enhance Governance and implement important business improvements. We have brought new seasoned leaders both to the Management and to the Board of Directors, increased the percentage of independent Board members from 40% at our IPO nearly four years ago to 90% currently and we have restructured our strategic management and reporting into two clear business areas: Financial Platform and Software Solutions. We have also taken important measures to better balance our strong growth with profitability. We will continue to execute on our strategy and our product roadmap to offer broader and better solutions to Brazilian merchants," said Andre Street, Chairman of the Board.

08:35 EDT NeuroSense enrolls first patient in Phase IIb trial of ALS candidate PrimeC - NeuroSense has enrolled the first patient in its Phase IIb PARADIGM trial for its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis, or ALS. PARADIGM will enroll 69 people living with ALS in Israel, Italy, and the U.S. Clinical trial endpoints include assessment of ALS-biomarkers, evaluation of clinical efficacy, and improvement in quality of life to demonstrate an attenuation in disease progression. NeuroSense expects to complete enrollment by the end of 2022 and to report top-line results in Q2 2023. . The Phase IIb study is designed to utilize an optimized dose and improved formulation which aims to maximize the synergistic effect between the compounds in the combination drug, relative to the formulation used in the prior Phase IIa study.

08:33 EDT Ryman Hospitality closes acquisition of Block 21 from Stratus Properties - Ryman Hospitality Properties (RHP) has closed its previously announced pending acquisition of Block 21 from Stratus Properties Inc. (STRS). The mixed-use complex is located in the heart of downtown Austin and is home to lodging, retail, office and entertainment spaces, including the W Austin Hotel and the ACL Live at Moody Theater. The purchase price for the acquisition, subject to certain purchase price adjustments, totaled approximately $260M, which includes the assumption of approximately $136M of existing mortgage debt.

08:31 EDT Capital One launches Capital One Software business - Capital One Financial announced the launch of Capital One Software, a new enterprise B2B software business focused on providing cloud and data management solutions for companies operating in the cloud. Capital One Software's first product is Capital One Slingshot, a data management solution for customers of Snowflake, the Data Cloud company, that is designed to help businesses accelerate adoption of the Snowflake Data Cloud, manage cloud costs, and automate critical governance processes.

08:30 EDT Wells Fargo feels good about cost savings goals, says CEO Scharf

08:30 EDT Wells Fargo CEO Scharf: Bank not immune to inflation

08:19 EDT Horizon says KRYSTEXXA plus methotrexate can change ''course of care' - Horizon Therapeutics announced the presentation of new KRYSTEXXA, pegloticase injection, datasets on the primary endpoint results from the MIRROR randomized clinical trial and analyses of the pharmacokinetics of KRYSTEXXA plus methotrexate. Additional presentations by Horizon during The EULAR 2022 European Congress of Rheumatology, June 1 - 4 in Copenhagen, include the exploratory findings from the PROTECT trial of KRYSTEXXA with immunomodulation in kidney transplant patients and the impact of chronic gout refractory to conventional therapies . "Substantial evidence shows KRYSTEXXA plus methotrexate can change the course of care for patients," said Theresa Podrebarac, M.D., MSc., senior vice president, clinical development, Horizon. "Results from the MIRROR randomized controlled trial reflects Horizon's significant investment in the research and development of KRYSTEXXA to improve patient outcomes and show a clear increase in patient response rate and reduction in infusion reactions. This multi-year effort and collaboration with the medical community brings new hope to address the burden of disease for people living with uncontrolled gout." ...Systemic exposures of KRYSTEXXA and its immunogenicity in uncontrolled gout patients were evaluated during the MIRROR randomized controlled trial to determine methotrexate exposure in uncontrolled gout patients through Month 6 of treatment with KRYSTEXXA plus oral methotrexate . Preinfusion blood samples were collected to measure methotrexate polyglutamates in red blood cells. Pre and postinfusion serum samples were also obtained to measure trough and peak concentrations of KRYSTEXXA, respectively, at multiple visits.

08:15 EDT Elys Game Technology to operate BetDupont sportsbook in Washington D.C. - Elys Game Technology announced the agreement to operate the BetDupont sportsbook with District Hospitality located at 1813 M St. NW in Washington D.C. BetDupont, situated in the Dupont Circle area of Washington, DC, is a lounge bar featuring table and cigar service and full-service Mediterranean/American fusion dining experience. If successfully licensed, the partnership with District Hospitality would represent the company's fourth execution of its restaurant sportsbook solution.

08:14 EDT Rail Vision receives Japanese patent allowance for railway obstacle detection - Rail Vision announced it received notice of allowance from the Japan Patent Office for its patent titled, "System and Methods for Object and Obstacle Detection and Classification in Collision Avoidance of Railway Applications," covering the Company's cutting-edge, artificial intelligence based, industry-leading technology specifically designed for railways. "Rail Vision's technology, which enables the identification and classification of objects on and around the tracks is a game changer," commented Rail Vision CEO Shahar Hania. "Japan has one of the most advanced rail networks in the world with more than 27,000 kilometers of track that carry an estimated 180 million passengers annually, in addition to a large volume of freight. With IP protections now in place in Japan, Rail Vision can enter this large market from a position of strength as we bring new advancements to the rail industry designed to save lives, increase efficiency, and dramatically reduce expenses for railway operators." The new Japanese patent was allowed by the Japanese Patent Office on May 10, 2022, and covers a system for the detection and identification of objects and obstacles near, between, or on the railway.

08:13 EDT Clearmind granted patent approval for alcohol substitute in India - Clearmind Medicine has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India. The patent refers to the company's proprietary MEAI-based alcohol substitute patent family. "Our innovation continues to gain global recognition, this time by the Indian patent office." said Dr. Adi Zuloff- Shani, Clearmind's Chief Executive Officer. "Clearmind is the sole owner of a family of patents concerning a synthetic substance as a replacement for alcohol. We will address the tremendous global problem of alcohol abuse by developing both approved treatments and food supplements," she added.

08:11 EDT VBI Vaccines receives UK MHRA marketing authorization for PreHevbri - VBI Vaccines announced that the UK Medicines and Healthcare Products Regulatory Agency, or MHRA, has granted marketing authorization for PreHevbri for active immunization against infection caused by all known subtypes of the hepatitis B virus, or HBV, in adults. It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D does not occur in the absence of hepatitis B infection. UK marketing authorization follows the European Commission's, or EC, centralized marketing authorization received in April and was conducted as part of the EC Decision Reliance Procedure, or ECDRP. VBI expects to make PreHevbri available in the UK in early 2023.

08:11 EDT AtriCure appoints Deborah Yount Chief Human Resources Officer - AtriCure announced the appointment of Deborah Yount as Chief Human Resources Officer, effective . Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profound, and I'm looking forward to having Deborah's partnership in this leadership role, helping us live out our mission."

08:10 EDT Applied Genetic announces formation of SAB - Applied Genetic Technologies announced the formation of a scientific advisory board, SAB, comprised of leading experts in age-related macular degeneration, AMD. The SAB will provide guidance on AGTC's development of Complement Factor H, intended for the treatment of dry AMD, and the company's plans to advance it through preclinical testing and into clinical development. The inaugural members of the SAB are: David Boyer, MD; David Brown, MD, FACS; Jeffrey Heier, MD; Nancy Holekamp, MD; Peter Kaiser, MD; Arshad Khanani, MD, MA; David Lally, MD, FASRS; Charles Wykoff, MD, PhD

08:09 EDT Ameresco, Bright Canyon Energy to build solar and battery project in Hawaii - Ameresco and Bright Canyon Energy announced the proposed Kpono Solar Project, a combined solar and battery system to be built at the Joint Base Pearl Harbor-Hickam West Loch Annex in Hawaii. The proposed project is designed to deliver 42 megawatts of clean, renewable energy to Hawaiian Electric's grid on the island of O'ahu. Ameresco has been implementing energy solutions in Hawai'i for over 15 years. Similarly, Bright Canyon has been developing energy infrastructure solutions since 2014. In 2021, Ameresco and Bright Canyon established a joint venture known as Kpono Solar Development Company to partner together to advance the Kpono Solar Project. This is the first project for the joint venture to focus on renewable energy, energy security and resiliency on O'ahu. In support of a Department of Defense long-term energy security initiative, Kpono Solar signed a 37-year land lease with the Navy to provide critical energy resiliency upgrades. The lease provides the use of approximately 131 acres of underutilized lands within the Navy West Loch Annex of Joint Base Pearl Harbor-Hickam. The project includes the installation of a 42 MW photovoltaic solar array and 42 MW/168 MWh of lithium-ion battery storage system. The batteries will store solar energy beyond sunset hours, enabling the project to deliver sustainable, renewable energy to power approximately 10,000 homes on O'ahu. In addition, this clean energy project will be designed to reduce more than 50,000 tons of carbon dioxide annually from Hawai'i's environment - the equivalent to offsetting emissions from 12,000 cars every year.

08:07 EDT Grom Social's Top Draw signs $950,000 in new animation assignments - Top Draw Animation, a division of Grom Social Enterprises, has secured an additional $950,000 in animation production assignments, it was announced by Top Draw's President, Russell Hicks. Top Draw produces animated series, movies, specials and short-form content for several leading global and international entertainment providers.

08:06 EDT Achieve Life Sciences awarded $2.5M grant from NIDA to conduct Phase 2 trial - Achieve Life Sciences announced that it has been awarded $2.5M in grant funding from the National Institute on Drug Abuse of the National Institutes of Health to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. This grant award will provide funding that enables Achieve to initiate the Phase 2 ORCA-V1 clinical trial, which aims to evaluate the efficacy and safety of cytisinicline in approximately 150 adult nicotine e-cigarette users at 5 clinical trial locations in the United States. Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, will be the Principal Investigator of the trial.

08:05 EDT National Grid expands residential EV charging rebate program in Massachusetts - National Grid is expanding its Off-Peak Charging Rebate Program in Massachusetts with ev.energy, a global provider of managed electric vehicle charging software. The program allows customers to receive a discount on their charging by connecting their vehicle or home charger to National Grid's new mobile app called Charge Smart MA. National Grid electric customers in Massachusetts will have the ability to earn money back on their monthly bill by plugging in their vehicles during off-peak hours and tracking their charging. The program utilizes the Charge Smart MA app, built by ev.energy for National Grid customers.

08:04 EDT Cocrystal Pharma expands collaboration with NIAID for Covid protease inhibitors - Cocrystal Pharma announces a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases for exploratory preclinical studies to evaluate the potential of Cocrystal's 3CL protease inhibitors for the treatment of COVID-19. Under the NIAID collaboration, Cocrystal has provided its proprietary process chemistry information for its oral 3CL protease inhibitors and the NIAID will support a scale-up synthesis of a key intermediate of the oral 3CL protease inhibitors. "We are pleased to expand our collaboration with NIAID to support our ongoing API synthesis of Cocrystal's oral 3CL protease inhibitors," said Sam Lee, Ph.D., Cocrystal's President and co-interim CEO. "We are grateful to receive the NIAID's additional support and look forward to further expanding our collaborative work going forward."

08:03 EDT Bit Origin signs LOI to purchase 750 bitcoin miners for $5.63M - Bit Origin Limited announced that the company has entered into a Letter of Intent with an American Counterparty to purchase 750 Antminer S19j Pro Bitcoin Miners, which are expected to ramp up the hash rate of the company's miner fleet by 75,000 TH/s. The anticipated purchase of miners will increase the company's Bitcoin miners to 4,378 units, producing approximately 416.2 PH/s when all miners are operating at full capacity, and it is expected to produce 52.68 BTCs per month when all miners are deployed. Pursuant to the LOI, the company agrees to purchase 750 Antminer S19j Pro Bitcoin Miners in an aggregate value of $5.63M. The company expects to enter into a definitive agreement and expects the transaction to be completed in the coming weeks, subject to the customary conditions, and the miners are expected to be delivered to the company's U.S. mining facility upon assigning of the definitive agreement. As the transaction proceeds, the company will publicly disclose required information either through press releases or SEC filings, as appropriate.

08:00 EDT General Electric targeting $2B gross cost out in 2022 - The company is targeting $2B gross cost out in 2022 through productivity, restructuring, and sourcing actions. GE is on track with its plan to launch three independent companies. Comments taken from slides being presented at the Bernstein Strategic Decisions Conference.

07:54 EDT Delta jumps 2.5% in premarket trading after providing updated Q2 guidance

07:52 EDT Delta sees June quarter total unit revenues 7-8 pts better than expected - Sees capacity 1-2 points lower than planned. Sees non-fuel unit costs up 20%-22% vs. 2019.

07:50 EDT Ormat Technologies signs 20-year PPA with CC Power - Ormat Technologies announced the execution of a Power Purchase Agreement, PPA, with California Community Power, CC Power, a Joint Powers Agency consisting of numerous California Community Choice Aggregators. Energy deliveries under the portfolio PPA are expected to start in the second quarter of 2024, with the expectation that the entire portfolio covered under the new PPA will be online by the end of 2026. The portfolio PPA covers a term of 20 years and is comprised entirely of new projects currently under construction or in development in Nevada and California. "Ormat is thrilled to execute this portfolio PPA with CC Power and its members. This collaboration is another example of the benefits of geothermal as a reliable source of sustainable baseload energy," said Doron Blachar, CEO of Ormat Technologies. "In addition to the latest two PPAs we recently signed with NV Energy, this twenty-year PPA will enable Ormat to continue executing upon our multi-year growth trajectory. We are very pleased to help the western states meet their renewable energy goals and believe geothermal offers a reliable alternative to baseload needs as the United States moves towards a more sustainable future."

07:40 EDT Draganfly announces new heavy lift, high endurance drones - Draganfly announces the launch of its new North American-made Heavy Lift and Commander 3 XL Drones. Draganfly's Heavy Lift Drone is a versatile, industrial, multirotor unmanned aerial vehicle, UAV, that is designed to lift more and fly further. Draganfly's Commander 3 XL Drone is a high-endurance, weather-resistant, multirotor UAV that is designed for easy assembly and rapid deployment. "As drone use continues to rise, industry leaders are looking for sophisticated solutions that are versatile, reliable, and secure. Our Heavy Lift and Commander 3 XL Drones will help a variety of major markets improve their business outputs and profitability," said Cameron Chell, President and CEO of Draganfly.

07:38 EDT Knight Therapeutics assumes commercial activities for Exelon in Colombia - Knight Therapeutics (KHTRF) announced that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon in Colombia upon successful transfer of the marketing authorization. On May 26, 2021, Knight completed the acquisition of the exclusive rights to manufacture, market and sell Exelon in Canada and Latin America as well as the exclusive license to use the intellectual property and the Exelon trademark, from Novartis (NVS) within those territories.

07:36 EDT Sensei Biotherapeutics appoints Gallagher as Chief Business Officer - Sensei Biotherapeutics announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer. Gallagher joins Sensei from Binney Street Partners, where he served as managing director supporting repeat entrepreneurs and venture funds to build, partner and transact biotech companies.

07:33 EDT Passage Bio reports Edgar Cale named interim CEO as Bruce Goldsmith steps down - Passage Bio announced that the board of directors and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and CEO and a member of the board, effective immediately. The board has appointed Edgar B. "Chip" Cale, the current general counsel and corporate secretary, as interim CEO. Dr. Goldsmith will serve as a strategic advisor to management and the board for a transition period. Maxine Gowen, Ph.D., the company's chairwoman, has assumed the role of interim executive chairwoman of the board. The board has initiated a search for a permanent CEO.

07:26 EDT Societal CDMO selected by AmyriAD Pharma to provide CDMO services - Societal CDMO announced that it has been selected by AmyriAD Pharma to provide contract development and manufacturing organization, CDMO, services to support the ongoing clinical development of AD101. The compound, a novel T-type calcium channel modulator, is currently in clinical development for the treatment of Alzheimer's disease, AD. AmyriAD has successfully completed Phase 2 clinical trials of AD101 and is planning to initiate two Phase 3 studies of the compound. Under terms of the new contract, which is valued at nearly $1M, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101. These activities will be conducted in collaboration at Societal's CDMO facilities in Georgia and California. "The Clinical Trial Services segment of our suite of CDMO offerings represents a critical growth driver for Societal. Our new agreement with AmyriAD, which represents a significant CTS contract win for Societal, highlights the potential for this portion of our business to contribute as a key revenue source," said David Enloe, chief executive officer of Societal CDMO. "Also notable about this collaboration with AmyriAD is that it will feature contributions from our both our East and West Coast facilities, offering strong evidence for the benefits of our expanded footprint and the seamless nature through which we can collaborate across the country. AmyriAD is undertaking important work in the hunt for effective Alzheimer's disease treatments and we are honored to assist them in those efforts."

07:24 EDT Kymera Therapeutics to present preclinical data at EULAR 2022 Congress - Kymera Therapeutics will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis, a pre-clinical model of rheumatoid arthritis, at the EULAR 2022 Congress in Copenhagen, Denmark. "These data further establish proof-of-concept for Kymera's potent and selective STAT3 degraders in inflammatory and autoimmune disorders," said Anthony Slavin, Vice President, Immunology. "Our findings demonstrate that even limited degradation of STAT3 results in significant suppression of proinflammatory cytokines across several immune cell types, including monocytes and T cells. The ability to block Th17 development and cytokine release with STAT3 degradation, and the demonstration of how that translates in vivo in a mouse model of rheumatoid arthritis, underscores the potential for STAT3 targeting in the treatment of Th17-driven autoimmune diseases." Research highlights included: Kymera's investigational STAT3 degrader selectively and potently degraded STAT3 in human peripheral blood mononuclear cells and whole blood; STAT3 degradation abrogated STAT3 phosphorylation and MCP-1/CCL2 release by human monocytes more potently than JAK inhibition; STAT3 degradation inhibited CD4+ Th17 development and related cytokine production in vitro and prevented collagen-induced arthritis in mice.

07:23 EDT IBI Group announces acquisition of HotSpot - IBI Group announced that it has acquired mobility solutions provider, HotSpot. Founded in New Brunswick in 2013, HotSpot began addressing parking issues through technology and has since developed into a suite of integrated mobility solutions. "With a track record of creating complete mobility solutions, HotSpot's proven technology in Canada and inroads into the U.S. will strengthen our market portfolio of smart city solutions and support our strategic expansion goals in the U.S.," said IBI Group CEO, Scott Stewart. "We look forward to welcoming HotSpot's talented staff to IBI and continuing to expand and strengthen our expertise in the mobility sector."

07:20 EDT Verano announces exclusive partnership with The Weldon Project's Mission Green - Verano announced the launch of an exclusive partnership in support of The Weldon Project's Mission Green. Through this partnership, Verano will initiate a nationwide fundraising campaign on June 3 that will remain active throughout 2022, available exclusively at the Company's retail locations. The Company's exclusive partnership with Mission Green will mobilize employees, patients, adult-use customers and cannabis reform advocates to support the organization's ongoing cannabis social justice initiatives. In addition to its initial $50,000 donation to Mission Green, Verano will also leverage its extensive retail operations across nearly 100 dispensaries in 13 states to engage and educate dispensary visitors on Mission Green. "As one of the largest multi-state cannabis operators in the U.S., we're proud to partner with Weldon Angelos and the Mission Green team and use our scale to amplify our support for cannabis clemency and continue the fight to repeal the harmful, outdated cannabis laws that have negatively impacted countless communities and individuals for generations," said George Archos, Verano Founder and Chief Executive Officer. "The important work the Mission Green team facilitates in support of cannabis clemency initiatives and advocacy across the political spectrum is essential as we seek to right historical wrongs and create positive, meaningful changes in our society, with the ultimate goal of ending cannabis prohibition."

07:18 EDT Singing Machine announces new karaoke assortment across Walmart stores - The Singing Machine Company (MICS) announced its new line of karaoke products are now available at approximately 3,200 Walmart (WMT) stores nationwide. Announced earlier this month, the new 4-foot program will include suggested retail price points from $9.99 to $149 and include a wide range of karaoke machines, microphones, portable Bluetooth microphones, and a streaming computer microphone featuring new proprietary PitchLab vocal processing technology which will provide pitch-correction and dazzling vocal effects.

07:16 EDT Apellis submits NDA to FDA for pegcetacoplan for GA - Apellis Pharmaceuticals announced that the company has submitted a New Drug Application to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration. "Pegcetacoplan is the only treatment that has shown the potential to meaningfully slow disease progression across three large studies with a representative, real-world population of GA patients," said Jeffrey Eisele, Ph.D., chief development officer at Apellis. "With the submission of our marketing application in the United States, we are now one step closer towards our goal of bringing the first GA treatment to patients living with this relentless and irreversible disease." The NDA submission is based on results from the Phase 3 DERBY and OAKS studies at 12 and 18 months and the Phase 2 FILLY study at 12 months. In the studies, treatment with both monthly and every-other-month pegcetacoplan resulted in a clinically meaningful reduction of GA lesion growth across a broad, heterogenous population of more than 1,500 patients. Pegcetacoplan demonstrated a favorable safety profile in all three studies. The FDA decision on NDA filing acceptance is expected in August 2022. Apellis also plans to submit a marketing authorization application to the European Medicines Agency in the second half of 2022.

07:13 EDT Asante Gold announces acquisition of Chirano Gold Mine temporarily delayed - Asante Gold Corporation announces that the closing of its previously-announced acquisition of the Chirano Gold Mine has been temporarily delayed pending resolution of certain outstanding administrative matters. Following resolution and completion of such matters, the Company expects to proceed to closing of the Chirano Acquisition. All material terms of the Chirano Acquisition remain the same.

07:12 EDT Rezolute promotes Roberts to Chief Medical Officer - Rezolute announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer. Dr. Roberts joined Rezolute in 2017 as Vice President of Clinical Development and a member of the founding management team, with responsibilities that included oversight of preclinical, regulatory, and clinical operations functions.

07:11 EDT Clene to present new data from RESCUE-ALS study at ENCALS meeting - Clene announced the presentation of new data from the company's Phase 2 RESCUE-ALS study at the European Network to Cure ALS Meeting 2022 taking place June 1-3 in Edinburgh, Scotland. Data being presented include: Preclinical evidence for neuroprotection by CNM-Au8, using both human induced pluripotent stem cell and primary neural-glial models of ALS, indicate that catalytically-active gold nanocrystals of CNM-Au8 target energy metabolism by a novel mechanism holds promise as a new therapeutic strategy for the treatment of ALS. Newly released interim survival data from the long-term open label extension study demonstrate that early treatment decreased risk of mortality by 62% when compared to delayed treatment; and decreased mortality risk by 64% when participant survival is compared to individual participant ENCALS predicted median survival. The results from the RESCUE- ALS study provide evidence of safety and suggest efficacy of CNM-Au8 in patients with early ALS. The 36-week blinded period of RESCUE-ALS suggested efficacy benefits with CNM-Au8 treatment versus placebo: slowing ALS disease progression, decreasing the proportion of participants with a 6-point decline in the ALS Functional Rating Scale Revised and improving quality of life as measured by the ALS Specific Quality of Life questionnaire.

07:10 EDT Black Diamond Therapeutics appoints Sergey Yurasov as chief medical officer - Black Diamond Therapeutics announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer. In conjunction with the appointment of Dr. Yurasov, Karsten Witt, M.D., is transitioning from his current role as the company's Interim Chief Medical Officer to a clinical advisory role. Yurasov joins Black Diamond Therapeutics from Nuvation Bio, an oncology therapeutics company.

07:08 EDT CynergisTek wins $220K ransomware, 'dark web' deal with partner GroupSense - CynergisTek announces its first win with strategic partner GroupSense to provide ransomware readiness and dark web monitoring for a Midwest health system. CynergisTek will provide this client with greater visibility into the dark web by monitoring their public personas, domains, and services for malicious activity, as well as reviewing and monitoring their ransomware runbooks. The service will provide 24/7 on-call ransomware incident support and negotiation and will allow the client to proactively monitor their online reputation and prevent online threats. CynergisTek's strategic partnership with GroupSense has allowed for increased capabilities to serve the healthcare industry and protect organizations against the growing threat landscape. Customers can leverage these services as a part of our broader managed services.

07:07 EDT Beyond Air appoints Monson as Chief Medical Officer - Beyond Cancer, an affiliate of Beyond Air, announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. Dr. Monson, a founding partner of cCARE in 2008, oversaw its growth into the largest private practice oncology group in the state of California.

07:05 EDT Lava Therapeutics to present initial Phase 1/2a LAVA-051 trial data - LAVA Therapeutics N.V. announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma at the 2022 American Society of Clinical Oncology Annual Meeting taking place in Chicago and virtually June 3-7, 2022. In the Phase 1/2a clinical study of LAVA-051 in patients with CLL and MM, the primary objectives are to investigate safety and tolerability and determine the recommended Phase 2 dose, while the secondary objectives are to evaluate pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity. Acute myeloid leukemia patients will be included later in the study. In addition to the favorable safety profile demonstrated to date, LAVA-051 showed predictable and linear pharmacokinetics and on-mechanism pharmacodynamic parameters consistent with Vgamma9Vdelta2-T cell engagement, including increasing occupancy of LAVA-051 on patient Vgamma9Vdelta2-T cells and consistent increases in the expression of T-cell activation markers. In these initial data, potential signs of clinical anti-tumor activity were also observed: a CLL patient experienced early enlargement and tenderness of several CLL-affected lymph nodes followed by a regression of those lymph nodes, resulting in a stable disease assessment after 12 weeks of therapy in combination with a reduction in the peripheral blood leukemic cell count over five cycles of LAVA-051; a MM patient showed a 23% reduction in myeloma cell-produced M-protein levels in the blood.

07:05 EDT Tonix Pharmaceuticals announces issuance of US patent for TNX-801 - Tonix Pharmaceuticals announced that the United States Patent and Trademark Office, USPTO, issued U.S. Patent No. 11,345,896 to the Company on May 31, 2022. This patent, entitled "Synthetic Chimeric Poxviruses," includes claims covering synthetic horsepox virus, the basis for the Company's TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the Company's Recombinant Pox Virus, RPV, platform to protect against other pathogens, including SARS-CoV-2. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments. "This patent is an important milestone in protecting our expanding pipeline of vaccines that address known and potentially novel pathogens," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "TNX-801 is a horsepox-based live virus vaccine currently in development to protect against monkeypox and smallpox. TNX-18401 and TNX-18501 are designed to express the spike proteins from the SARS-CoV-2 omicron and BA.2 variants, respectively. Horsepox was one of the first few viruses ever generated by synthetic biology and remains among the largest. As we prepare to advance horsepox-based live virus vaccines into clinical development, we are excited to have this new patent as an important element of our patent estate."

07:03 EDT Foot Locker appoints Neil Bansal as Chief Strategy & Transformation Officer - Foot Locker appointed Neil Bansal as Executive VP and Chief Strategy & Transformation Officer, effective immediately. Bansal joins Foot Locker from Constellation Brands, where he served as Senior VP, Strategy, Insights & Analytics, bringing over 20 years of global experience leading end-to-end corporate strategy and development, transformation, innovation, and digital/data/analytics across consumer and retail businesses. Prior to his role at Constellation Brands, Neil held roles at companies including McKinsey & Company, BNP Paribas, JP Morgan Chase, Citigroup, and Bank of America.

06:59 EDT Capri Holdings jumps 8% to $52.80 after Q4 results, FY23 guidance top estimates

06:59 EDT vTv Therapeutics to receive $25M investment by G42 Investment - vTv Therapeutics announced entry into agreements that include a $25M investment by G42 Investments. Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5M paid in cash at closing, and the remaining amount of $12.5M payable on May 31, 2023. The agreements also provide for the potential issuance of $30M in additional shares of Class A Common Stock to G42 Investments if the FDA approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of type 1 diabetes in the U.S. The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42's affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42's affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories outside of the U.S. and the EU.

06:56 EDT Roper Technologies to sell majority stake in industrial businesses to CD&R - Roper Technologies announced that it has agreed to sell a majority stake in its industrial businesses, including its entire Process Technologies segment and the industrial businesses within its Measurement & Analytical Solutions segment, to affiliates of Clayton, Dubilier & Rice, LLC. Roper will receive total upfront, pre-tax cash proceeds of approximately $2.6B while retaining a 49% minority interest in a new standalone entity. The transaction includes the following businesses: Alpha, AMOT, CCC, Cornell, Dynisco, FTI, Hansen, Hardy, Logitech, Metrix, PAC, Roper Pump, Struers, Technolog, Uson, and Viatran. Collectively, these businesses generated approximately $940M of revenue and $260M of EBITDA in 2021. Beginning in the second quarter of 2022, Roper plans to report the results of these businesses as discontinued operations. Following the closing of this transaction, Roper's ownership interest in the new standalone entity will be reported as income from minority interest. The company expects this transaction to close by the end of 2022, subject to customary closing conditions.

06:53 EDT TransUnion appoints Karen Krause as Chief Strategy and Communications Officer - TransUnion has hired Karen Krause as Executive VP, Chief Strategy and Communications Officer, effective June 1. Krause joins TransUnion from JPMorgan Chase, where she served most recently as Global Head of Product Enablement & Delivery, Integrated Payments Product Group. She previously worked in various strategy and corporate development roles at S&P Global, Goldman Sachs, TCR Private Equity and McKinsey.

06:52 EDT View Inc. expects to file its delinquent 10-K and 10-Q filings by June 30 - The company states: "Restated warranty-related accruals are within ranges previously disclosed on November 9th, 2021. View has not identified any additional material misstatements. Nasdaq has granted View until June 30, 2022, to file its delinquent 10-K and 10-Q filings, which View expects to file with the SEC on or prior to that date."

06:49 EDT CNX Resources promotes Donald Rush to CSO, Alan Shepard to CFO - CNX Resources announced executive leadership promotions. Donald Rush, CFO, will assume the role of chief strategy officer, or CSO, and Alan Shepard, VP and chief accounting officer, will be promoted to the role of CFO. Both moves are effective immediately.

06:43 EDT Macau reports May casino revenue down 68.0% to 3.34B patacas - Macau's gaming bureau reported May gross revenue from games of fortune in the region was down 68.0% year-over-year to 3.341B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO).

06:37 EDT Air Lease announces lease placement of three new Airbus A321 with Latam Airlines - Air Lease (AL) announced long-term lease placements for three new Airbus (EADSY) A321neo aircraft with Latam Airlines (LTMAQ). The aircraft are scheduled to deliver to LATAM in summer and fall of 2023 from ALC's orderbook with Airbus.

06:34 EDT AmerisourceBergen announces new $1B share repurchase program - In May, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the company to purchase up to $1B of its outstanding shares of common stock, subject to market conditions. The company's fiscal year 2022 guidance does not include any potential benefit from the $1B share repurchase authorization. As of May 31, the company had $321M remaining under the share repurchase program authorized in May 2020.

06:31 EDT Biolase creates integration team - Biolase announced that due to the growing adoption of its laser technology, Biolase has taken the step of creating a multi-dimensional integration team to support the optimal use of Biolase dental lasers in practices across North America.

06:18 EDT FSD Pharma submits IND application to FDA for Phase 2 trial of FSD-PEA - FSD Pharma has submitted an Investigational New Drug application with the U.S. Food and Drug Administration and Health Canada. The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.

06:13 EDT Radware, ONESECURE expand partnership - Radware announced the expansion of their partnership agreement. To enhance ONESECURE'S Webyith defacement and domain phishing monitoring service for ASEAN enterprises, the MSSP is expanding its cyber security suite to include Radware's Application Protection-as-a-Service offering and Cloud DDoS Protection Service. The enhancements will offer ONESECURE customers more robust, round-the-clock cyber protection, increased network visibility, and advanced application and API protection from web attacks, vulnerabilities, and bad bots. ONESECURE's security suite also includes Radware's DefensePro solution for automated DDoS protection and Radware's Alteon application delivery controller, which protects applications, while optimizing application performance and delivery.

06:12 EDT Landsea Homes to repurchase $30M in common stock from controlling holder - Landsea Homes announced that it has entered into an agreement to repurchase approximately $30M in shares of its common stock owned by Landsea Holdings Corporation, the company's controlling stockholder, at a repurchase price of $6.82 per share, an approximate 5% discount to the closing price of the company's common stock on May 31, the day before the repurchase agreement was signed. The repurchase represents a 15.9% discount to the 30-day volume-weighted average price of $8.11. The terms of the transaction were unanimously approved by a Special Committee of the Company's Board of Directors consisting entirely of independent directors who are not affiliated with LHC or any of its affiliates and the company's Audit Committee under the company's related party transaction policy. The repurchase will be funded with cash on hand and is expected to close on or about June 2, after which LHC is expected to own approximately 23.6M shares of the company's common stock, representing approximately 57.8% of the outstanding shares. LHC also agreed to a lock-up of its shares of the company's common stock for the 90-day period from the date of the repurchase agreement, subject to limited exceptions.

06:10 EDT Genetron receives CE Mark for FusionScan Plus Kit - Genetron announced it has obtained a CE Mark for its FusionScan Plus Kit, an integrated DNA and RNA NGS-based assay for simultaneously detecting multiple gene mutations and fusions with lower thresholds. Receipt of the CE Mark is an important step for the acceleration of FusionScan Plus's global footprint, and its potential to enter more international clinical trials in the future.

06:09 EDT Donaldson sees FY22 CapEx $90M-$100M - Fiscal 2022 capital expenditures are projected to be between $90M-$100M. Free cash flow conversion is expected to be between 50%-60%, down from previous guidance of between 70%-80% due to increased levels of inventory to manage supply chain challenges as well as higher accounts receivable from higher sales. Donaldson is increasing its share repurchase expectation to be between 2.0%-2.5% of shares outstanding from approximately 2.0% previously.

06:08 EDT Donaldson CEO sees Q4 'sequential sales and gross margin improvement' - "Our record third quarter sales were driven by pricing actions offsetting persistent inflation, as well as continued high levels of demand," said Tod Carpenter, chairman, president and CEO. "Undeterred by the macro challenges, our team maintained a strong commitment to providing technology-led filtration to customers as global demand for our products and services remained at record highs. Looking ahead, we anticipate ongoing inflation and supply chain constraints. However, the successful execution of pricing actions by the Donaldson team throughout this fiscal year is expected to drive fourth quarter sequential sales and gross margin improvement. As we close out the year, we remain focused on delivering on our customer commitments, implementing pricing actions to offset cost pressures and investing for the future."

06:06 EDT Park Hotels & Resorts to sell 25% interest in JV in Hilton San Diego Bayfront - Park Hotels & Resorts (PK) announced that it has entered into a definitive agreement with affiliates of Sunstone Hotel Investors (SHO) for Park to sell its 25% interest in the joint venture owning the 1,190-room Hilton San Diego Bayfront to Sunstone for a sale price of $102 million plus Park's allocated share of reserves and working capital. The sale price represents a $628M valuation for the Hilton Bayfront, or approximately $528,000 per key, after accounting for the $220M secured loan in place on the asset. The sale price represents a 6.5% capitalization rate on the hotel's 2019 net operating income, or 13.4x the Hotel's 2019 EBITDA. The closing will be subject to customary closing conditions and third-party consents.

05:37 EDT NIO delivers 7,024 vehicles in May - Nio announced its May delivery results. NIO delivered 7,024 vehicles in May. The deliveries consisted of 5,317 smart electric SUVs, including 746 ES8s, 2,936 ES6s and 1,635 EC6s, and 1,707 ET7s. As of May 31, cumulative deliveries reached 204,936 vehicles. In May, the company's vehicle production had been gradually recovering from the impact of COVID-19 outbreaks in certain regions in China while vehicle deliveries were still constrained to a certain extent by the corresponding preventive measures. Nio plans to further ramp up the production capacity to a higher level by working closely with supply chain partners and to accelerate the delivery recovery starting from June, in light of the recent supportive developments in the COVID-19 situation and the strong order inflow.

05:28 EDT Snam purchases FSRU from Golar LNG for $350M - Snam and Golar LNG have signed an agreement for the Snam Group to acquire 100% of the share capital of Golar LNG NB 13 Corporation, whose sole asset is a floating storage and regasification unit, or FSRU, named "Golar Tundra", for $350M. The transaction was approved by the Golar board of directors on May 30. The Golar Tundra can operate both as an LNG carrier and as an FSRU. The vessel, built in 2015, has a storage capacity of around 170,000 cubic meters of LNG and a continuous regasification capacity of 5B cubic meters per year. In order to maximize its regasification capacity, the vessel will be located in central-northern Italy, close to the areas with greatest gas consumption. The Golar Tundra is expected to start operations as an FSRU during the spring of 2023, subject to completion of authorization, regulatory processes and the construction of the necessary infrastructure connecting the terminal to the existing gas transport network.

05:22 EDT GXO Logistics opens new pharmaceutical warehouse in Milan - GXO Logistics announced the opening of a new warehouse dedicated to the pharmaceutical sector. Located in Caleppio di Settala, the 20,000-square-meter facility will be equipped with technology and environmental systems. GXO's team of pharmaceutical industry experts will attend the 61st Simposio AFI in Rimini, Italy, June 8-10. The site, scheduled to open in the second quarter of 2022, is strategically located to meet the needs of Italy's pharmaceutical sector. The warehouse layout has been optimized for all storage, distribution, co-packing and returns management activities, including a prescription medications and a quarantine Good Manufacturing Practice, or GMP, area. The use of energy-efficient equipment will allow GXO to keep the entire warehouse at a controlled temperature, with different ranges depending on the needs of specific products and activities.

05:16 EDT Appian opens new office in Seville - Appian announced the opening of its newest office in Europe and its first Technology Innovation Center in Seville, Spain, as the demand for the Appian Low-Code Platform continues to grow in the region. Situated right in the heart of the Cartuja Science and Technology Park, Appian plans to recruit and hire locally to serve its growing list of customers and partners in Europe, the Middle East and Africa, or EMEA.

05:12 EDT Li Auto delivers 11,496 Li ONEs in May - Li Auto announced that the company delivered 11,496 Li ONEs in May, up 165.9% year over year. The cumulative deliveries of Li ONE have reached 171,467 since the vehicle's market debut in 2019. "Although our parts suppliers in the Yangtze Delta region have gradually resumed production, they have not yet fully recovered and we continue to encounter challenges due to parts supply shortages. As such, our Changzhou manufacturing base has not yet reverted to its normal production level, resulting in delayed deliveries for some of our users. At present, we are actively collaborating with our supply chain partners to restore production capacity, aiming to shorten the delivery waiting time for Li ONE users, while meeting all pandemic prevention and containment requirements," commented Yanan Shen, co-founder and president of Li Auto.

05:07 EDT Xpeng delivers 10,125 Smart EVs in May - XPeng announced its vehicle delivery results for May. XPeng delivered 10,125 Smart EVs in May, representing a 78% increase year-over-year. The May deliveries consisted of 4,224 P7 smart sports sedans, 3,686 P5 smart family sedans, as well as 2,215 G3 smart compact SUVs. As of May 31, year-to-date total deliveries reached 53,688, representing a 122% increase year-over-year. The company resumed double-shift production at its Zhaoqing plant beginning in mid-May as supply chains and key manufacturing areas in China started to gradually recover.